Biotech/Pharmaceuticals

Try Jim Cramer's Action Alerts PLUS
CLICK HERE NOW

Cancer Drug Data Fail to Lift Genentech

06/07/04 - 02:18 PM EDT

TSC Staff

Updated from 8:45 a.m. EDT

Shares in OSI Pharmaceuticals(OSIP - Cramer's Take - Stockpickr) and Genentech(DNA - Cramer's Take - Stockpickr) slipped Monday despite positive test data on a cancer drug the two companies are developing.

Data presented at the American Society of Oncology's annual meeting Saturday showed the companies' Tarceva treatment increased survival by 42% in patients with end-stage non-small-cell lung cancer.

Shares in both companies rose in early trading, but then fell back. Genentech shares fell $3.10, or 5.2%, to $56.31 while OSI shares lost $4.51, or 5.7%, to $74.02.

"This trial is important because a survival treatment benefit was achieved among a broad group of patients," said Genentech's chief medical officer of the phase III testing.

OSI is expected to seek marketing approval for Tarceva from the Food and Drug Administration this summer.

Swiss drugmaker Roche will market the drug overseas if and when it is approved.

The companies said "more detailed presentations of the data" will be made at the society's meeting today.


Previous Story

Dyax Jumps on FDA Move

Headlines & Perspectives

Biotech/Pharmaceuticals

Go To Section Home



08/05/08
Three Internet Stocks That Could Double

These forgotten Internet stocks are being accumulated by hedge funds.


08/15/08
The Five Dumbest Things on Wall Street

Raspberries for Apple; You'll be sorry, UBS; Fortress or Fort Knox? Wholly unappetizing Foods; give Liberty AOL or give them...


08/15/08
McCain Fund-Raising Picks Up

The GOP presidential candidate raised $27 million in July.


08/15/08
Cash-Back Cards Aren't Money in the Bank

Some credit and debit cards give you some cash back on purchases. But you need to manage it well to benefit from it.


Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Sign up for our FREE newsletters now. See All

  • Cramer's Daily Booyah!
  • Before the Bell

Premium Stock Ideas
Access Action Alerts Plus to find out Cramer’s latest picks now!